Eton Pharmaceuticals Inc (NASDAQ:ETON) CEO Sean Brynjelsen purchased 5,000 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was bought at an average price of $6.15 per share, with a total value of $30,750.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Sean Brynjelsen also recently made the following trade(s):
- On Tuesday, May 21st, Sean Brynjelsen purchased 10,000 shares of Eton Pharmaceuticals stock. The stock was bought at an average price of $7.93 per share, with a total value of $79,300.00.
Shares of ETON traded down $0.18 during trading hours on Tuesday, reaching $5.93. The company had a trading volume of 148,479 shares, compared to its average volume of 46,533. The firm has a 50 day moving average of $6.94. The company has a quick ratio of 11.48, a current ratio of 11.48 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $106.76 million and a P/E ratio of -1.02. Eton Pharmaceuticals Inc has a 12-month low of $5.70 and a 12-month high of $10.20.
Eton Pharmaceuticals (NASDAQ:ETON) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.12. Equities research analysts predict that Eton Pharmaceuticals Inc will post -1.04 earnings per share for the current year.
A number of equities analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.00 price target for the company in a report on Monday. ValuEngine upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Eton Pharmaceuticals in a report on Monday, August 5th. Finally, Lake Street Capital assumed coverage on shares of Eton Pharmaceuticals in a report on Monday, August 5th. They issued a “buy” rating for the company.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
Recommended Story: What does an outperform rating mean?
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.